Common eye conditions are linked to increased risks for incident attention-deficit/hyperactivity disorder, particularly in women and in the pediatric population, a retrospective study shows. Medscape Medical News
Author: Medscape
Advice on Recognizing and Managing Sjӧgren Disease
Dr Nancy Carteron urges clinicians to learn to recognize how Sjӧgren disease could be hiding in plain sight and why early care is more essential than ever. Medscape
When Eye Problems Signal a Wider Immune Issue and Vice Versa
Patients with immune-mediated diseases face a high risk for incident uveitis, and those with uveitis face a high risk of developing or already having an immune-mediated disease, a recent study shows. Medscape Medical News
Eyeing Topical Options for Night Driving Problems
Impaired night vision affects 25 million Americans. Studies suggest topically reducing pupil size might help, especially for halo or starburst effects after refractive surgery. Medscape Medical News
Open-Angle Glaucoma Tied to Early-Onset Alzheimer’s Disease
Open-angle glaucoma is linked to an increased risk for early-onset Alzheimer’s disease in middle-aged adults, especially men, a new study shows. Medscape Medical News
Advice on the Challenges in Managing Sjögren Disease
Dr Teja Kapoor urges early-career clinicians not to underestimate Sjögren’s disease, which requires thorough testing and multidisciplinary collaboration. Medscape
Overcoming Barriers in Sjögren Disease Care
Dr Teja Kapoor explores how cultural sensitivity and awareness can overcome barriers to timely Sjögren disease management in diverse communities. Medscape
Eye Vessel Blockages: Early Warning for Alzheimer’s Disease?
Patients with retinal vascular occlusion had an elevated risk for Alzheimer’s disease and related dementias, new research shows. Medscape Medical News
Eye Vessel Blockages: Early Warning for Alzheimer’s Disease?
Patients with retinal vascular occlusion had an elevated risk for Alzheimer’s disease and related dementias, new research shows. Medscape Medical News
Eye Problems Tied to Osteonecrosis in Bisphosphonate Users
Patients who experience adverse ocular effects with bisphosphonates have a notably higher risk for osteonecrosis than those who do not experience such events, a large cohort study shows. Medscape Medical News
US FDA Declines to Approve Outlook’s Eye Disease Drug for Second Time in 2025
Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, dealing another blow in the company’s prolonged… Reuters Health Information
No Complications With First Human Robotic Cataract Surgery
A small proof-of-concept study of robotic-assisted cataract surgery reports successful outcomes with no treatment-related adverse events. Medscape Medical News
The 12 Dangers of Christmas
Echoing the 12 Days of Christmas, this festive guide outlines the seasonal risks clinicians can help patients avoid. Medscape News UK
Aflibercept 8 mg Promising Alternative to 2 mg for PCV
Aflibercept 8 mg provides similar outcomes for vision and eye structure as the 2-mg dose in patients with polypoidal choroidal vasculopathy, a recent study finds. Medscape Medical News
Secukinumab Fails to Show Benefit in Graves’ Orbitopathy
Secukinumab does not show greater clinical efficacy than placebo in patients with moderate-to-severe Graves’ orbitopathy, according to the ORBIT study. Medscape News UK
Levodopa May Help Prevent Progression to Neovascular AMD
A new study shows that in patients with intermediate nonneovascular age-related macular degeneration, levodopa treatment is linked to a lower risk of developing the neovascular form of the disease. Medscape Medical News
Heart Risks May Rise and Persist After Transient Vision Loss
Transient loss of vision is associated with an increased risk for cardiovascular events within 14 days of diagnosis, and risks may persist for up to 10 years, a study finds. Medscape Medical News
Biosimilars for Retina and Inflammatory Disease Get EMA Nod
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs. Medscape News Europe
Biosimilars for Retina and Inflammatory Disease Get EMA Nod
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs. Medscape News Europe
Immunotherapy for Cat Allergy Shows Favorable Safety Profile
A depigmented polymerized cat allergoid is safe and generally well tolerated in patients with cat-induced allergic rhinitis, a real-world study finds. Medscape Medical News